Overview

A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Willi Syndrome

Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
This is a seamless Phase 2/3, double-blind, randomized, placebo-controlled clinical study in patients diagnosed with PWS. Following consent (or legal guardian consent and patient assent as appropriate), patients will be screened for eligibility to participate in this study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Radius Pharmaceuticals, Inc.